Comment on

• Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial.

  Rosenzwajg M, Lorenzon R, Cacoub P, Pham HP, Pitoiset F, El Soufi K, RIbet C, Bernard C, Aractingi S, Banneville B, Beaugerie L, Berenbaum F, Champey J, Chazouilleres O, Corpechot C, Fautrel B, Mekinian A, Regnier E, Saadoun D, Salem JE, Sellam J, Seksik P, Daguenel-Nguyen A, Doppler V, Mariau J, Vicaut E, Klatzmann D. Rosenzwajg M, et al. Ann Rheum Dis. 2019 Feb;78(2):209-217. doi: 10.1136/annrheumdis-2018-214229. Epub 2018 Nov 24. Ann Rheum Dis. 2019. PMID: 30472651 Clinical Trial.
• Circulating regulatory T cells were absolutely decreased in dermatomyositis/polymyositis patients and restored by low-dose IL-2.

  Zhang SX, Wang J, Sun HH, Zhang JQ, Liu GY, Luo J, He PF, Li XF. Zhang SX, et al. Ann Rheum Dis. 2021 Aug;80(8):e130. doi: 10.1136/annrheumdis-2019-216246. Epub 2019 Oct 14. Ann Rheum Dis. 2021. PMID: 31611221 No abstract available.